Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development

被引：3

作者：

Feemster, Kristen ^{[1
]}

Hausdorff, William P. ^{[2
,3
]}

Banniettis, Natalie ^{[1
]}

Platt, Heather ^{[1
]}

Velentgas, Priscilla ^{[1
]}

Esteves-Jaramillo, Alejandra ^{[1
]}

Burton, Robert L. ^{[4
]}

Nahm, Moon H. ^{[5
]}

Buchwald, Ulrike K. ^{[1
]}

机构：

[1] Merck & Co Inc, Rahway, NJ 07065 USA

[2] PATH, Ctr Vaccine Innovat & Access, 455 Massachusetts Ave NW, Washington, DC 20001 USA

[3] Univ Libre Bruxelles, Fac Med, B-1050 Brussels, Belgium

[4] SunFire Biotechnol LLC, Birmingham, AL 35203 USA

[5] Univ Alabama Birmingham, Heersink Sch Med, Birmingham, AL 35233 USA

来源：

VACCINES | 2024年 / 12卷 / 09期

关键词：

cross-reactivity; cross-protection; pneumococcal vaccines; PCVs; Streptococcus pneumoniae; NONTYPABLE HAEMOPHILUS-INFLUENZAE; ACUTE OTITIS-MEDIA; PNEUMONIAE SEROTYPES 6C; D CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; CAPSULAR POLYSACCHARIDE; PROTEIN-D; INVASIVE DISEASE; HUMAN-ANTIBODIES; UNITED-STATES;

D O I：

10.3390/vaccines12090974

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Pneumococcal vaccines are a cornerstone for the prevention of pneumococcal diseases, reducing morbidity and mortality in children and adults worldwide. Pneumococcal vaccine composition is based on the polysaccharide capsule of Streptococcus pneumoniae, which is one of the most important identified contributors to the pathogen's virulence. Similarities in the structural composition of polysaccharides included in licensed pneumococcal vaccines may result in cross-reactivity of immune response against closely related serotypes, including serotypes not included in the vaccine. Therefore, it is important to understand whether cross-reactive antibodies offer clinical protection against pneumococcal disease. This review explores available evidence of cross-reactivity and cross-protection associated with pneumococcal vaccines, the challenges associated with the assessment of cross-reactivity and cross-protection, and implications for vaccine design and development.

引用

页数：22

共 50 条

[1] CROSS-REACTIVITY AND CROSS-PROTECTION IN MURINE MALARIA
SEDEGAH, M
TOSTA, CE
HENDERSON, DC
WEDDERBURN, N
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 1982, 76 (02): : 219 - 221
[2] Cross-reactivity reduced dengue virus 2 vaccine has no cross-protection against heterotypic dengue viruses
Galula, Jedhan U.
Yang, Chung-Yu
Davis, Brent S.
Chang, Gwong-Jen J.
Chao, Day-Yu
FUTURE VIROLOGY, 2020, 15 (02) : 79 - 90
[3] Immunogenic Cross-Reactivity between Goose and Muscovy Duck Parvoviruses: Evaluation of Cross-Protection Provided by Mono- or Bivalent Vaccine
Palya, Vilmos
Zolnai, Anna
Felfoldi, Balazs
VACCINES, 2022, 10 (08)
[4] Immunogenic cross-reactivity between different serotypes novel duck reoviruses: Evaluation of cross-protection provided by mono or bivalent vaccine
Huang, Dong
Shao, Yu
Wang, Ruizhi
Liu, Sijia
Zhang, Shilei
Bao, Shijun
POULTRY SCIENCE, 2025, 104 (04)
[5] Trends in development of the influenza vaccine with broader cross-protection
Stropkovska, A.
Janulikova, J.
Vareckova, E.
ACTA VIROLOGICA, 2010, 54 (01) : 7 - 19
[6] Eliminating vaccine cross-reactivity
Sarah Crunkhorn
Nature Reviews Drug Discovery, 2019, 18 (11) : 826 - 826
[7] CROSS-REACTIVITY AND VACCINE DESIGN
GERSHONI, JM
DENISOVA, G
RAVIV, D
STERN, B
ZWICKEL, J
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 : S133 - S133
[8] Cross-protection from HPV vaccine
不详
EUROPEAN JOURNAL OF CANCER, 2009, 45 (13) : 2230 - 2230
[9] Confirming cross-protection of bivalent HPV vaccine
Brotherton, Julia M. L.
LANCET INFECTIOUS DISEASES, 2017, 17 (12): : 1227 - 1228
[10] A DIVA vaccine for cross-protection against Salmonella
Bearson, Bradley L.
Bearson, Shawn M. D.
Kich, Jalusa D.
VACCINE, 2016, 34 (10) : 1241 - 1246

← 1 2 3 4 5 →